Hip fractures are
among the most common types of fracture risks
in old age osteoporotic patients that often end up with immobile disabilities.
Weak bones due to loss of mineral content along with an increase in
the porosity of the femur neck canal in osteoporosis reduce the mechanical
properties of the bone and predispose the patients to fractures. In
this study, we have used calcium sulfate/nanohydroxyapatite based
nanocement (NC) as carrier of recombinant human bone morphogenetic
protein-2 (BMP-2), zoledronate (ZA), and bone marrow mesenchymal stromal
cells (MSCs) derived exosomes (EXO) to enhance bone formation and
defect healing in a femur neck canal defect model in osteoporotic
rats. A cylindrical defect in the femur neck canal with dimensions
of 1 mm (diameter) × 8 mm (length) starting from the lateral
cortex toward the apex of the femur head was developed. The defect
was impacted using NC alone or functionalized as (a) NC + ZA (systemic),
(b) NC + ZA (local), (c) NC + EXO + ZA, and (d) NC + BMP + ZA to evaluate
bone formation by ex vivo micro-computed tomography (micro-CT) and
histological analysis 16 weeks postsurgery. Moreover, the femurs (both
defect and contralateral leg) were subjected to biomechanical analysis
to assess the effect of treatments on compressive mechanical properties
of the bones. The treatment groups (NC + ZA (L), NC + BMP + ZA, and
NC + EXO + ZA) showed enhanced bone formation with complete healing
of the defect. No differences in the mechanical properties of both
the defect and contralateral across the leg were observed among the
groups. However, a trend was observed where NC + BMP + ZA showed enhanced
biomechanical strength in the defect leg. This suggests that NC could
act as a potent carrier of bioactive molecules to reduce the risks
of hip fractures in osteoporotic animals. This type of treatment can
be given to patients who are at higher risk of osteoporosis mediated
femur neck fracture as a preventive measure or for enhanced healing
in already compromised situations. Moreover, this study provided a
proof of concept regarding the use of exosomes in bone regeneration
therapy, which might be used as a booster dose that will eventually
reduce the dosage of BMP and hence circumvent the limitations associated
with the use of BMP.